The Differential Radial Capillary Action of Ligand Assay (DRaCALA) can be used to identify small ligand binding proteins of an organism by using an ORFeome library.
The past decade has seen tremendous progress in the understanding of small signaling molecules in bacterial physiology. In particular, the target proteins of several nucleotide-derived secondary messengers (NSMs) have been systematically identified and studied in model organisms. These achievements are mainly due to the development of several new techniques including the capture compound technique and the differential radial capillary action of ligand assay (DRaCALA), which were used to systematically identify target proteins of these small molecules. This paper describes the use of the NSMs, guanosine penta- and tetraphosphates (p)ppGpp, as an example and video demonstration of the DRaCALA technique. Using DRaCALA, 9 out of 20 known and 12 new target proteins of (p)ppGpp were identified in the model organism, Escherichia coli K-12, demonstrating the power of this assay. In principle, DRaCALA could be used for studying small ligands that can be labeled by radioactive isotopes or fluorescent dyes. The critical steps, pros, and cons of DRaCALA are discussed here for further application of this technique.
Bacteria use several small signaling molecules to adapt to constantly changing environments1,2. For example, the autoinducers, N-acylhomoserine lactones and their modified oligopeptides, mediate the intercellular communication among bacteria to coordinate population behavior, a phenomenon known as quorum sensing2. Another group of small signaling molecules is the NSMs, including the widely studied cyclic adenosine monophosphate (cAMP), cyclic di-AMP, cyclic di-guanosine monophosphate (cyclic di-GMP), and guanosine penta- and tetra phosphates (p)ppGpp1. Bacteria produce these NSMs as a response to a variety of different stress conditions. Once produced, these molecules bind to their target proteins and regulate several different physiological and metabolic pathways to cope with the encountered stresses and enhance bacterial survival. Therefore, identification of the target proteins is an unavoidable prerequisite for deciphering the molecular functions of these small molecules.
The past decade has witnessed a boom of knowledge of these small signaling molecules, mainly due to several technical innovations that unveiled the target proteins of these small molecules. These include the capture compound technique3,4,5, and the differential radial capillary action of ligand assay (DRaCALA)6 to be discussed in this paper.
Invented by Vincent Lee and co-workers in 20116, DRaCALA deploys the ability of a nitrocellulose membrane to differentially sequester free and protein-bound ligands. Molecules such as proteins cannot diffuse on a nitrocellulose membrane, while small ligands, such as the NSMs, are able to. By mixing the NSM (e.g., ppGpp) with the protein to be tested and spotting them on the membrane, two scenarios can be expected (Figure 1): If (p)ppGpp binds to the protein, the radiolabeled (p)ppGpp will be retained in the center of the spot by the protein and will not diffuse outward, giving an intense small dot (i.e., strong radioactive signal) under a phosphorimager. However, if (p)ppGpp does not bind to the protein, it will diffuse freely outward to produce a large spot with uniform background radioactive signal.
Furthermore, DRaCALA can detect the interaction between a small molecule and an unpurified protein in a whole cell lysate if the protein is present in a sufficient amount. This simplicity allows the use of DRaCALA in rapidly identifying protein targets by using an ORFeome expression library. Indeed, target proteins of cAMP7, cyclic di-AMP8, cyclic di-GMP9,10, and (p)ppGpp11,12,13 have been systematically identified by using DRaCALA. This video article uses (p)ppGpp as an example to demonstrate and describe the critical steps and considerations in performing a successful DRaCALA screening. Of note, a more thorough description of DRaCALA14 is highly recommended to read in combination with this article before performing DRaCALA.
Figure 1: The principle of DRaCALA. (A) Schematic of the DRaCALA assay. See the text for details. (B) Quantification and calculation of the binding fraction. See the text for details. Briefly, the DRaCALA spots will be analyzed by drawing two circles that circumscribe the whole spot and the inner dark dot (i.e., the retained (p)ppGpp due to the binding of the tested protein). The specific binding signal is the radioactive signal of the inner circle (S1) after subtracting the non-specific background signal (calculated by A1 × ((S2-S1)/(A2-A1))). The binding fraction is the specific binding signal divided by the total radioactive signal (S2). Abbreviations: DRaCALA = Differential Radial Capillary Action of Ligand Assay; (p)ppGpp = guanosine penta- and tetraphosphates; RT = room temperature. Please click here to view a larger version of this figure.
1. Preparation of whole cell lysates
2. Purification of Relseq and GppA
NOTE: The recombinant proteins Relseq from Streptococcus equisimilis and GppA from E. coli K-12 are used to synthesize the radiolabeled pppGpp and ppGpp, respectively.
3. Synthesis of 32P-labeled pppGpp and ppGpp
Volume (μL) | ||
Small scale | Large scale | |
Ultrapure water | ||
10x Relseq buffer* | 2 | 50 |
ATP (8 mM final) | ||
Relseq (4 μM final) | ||
32P-α-Guanosine triphosphate (GTP) (final 120 nM) (CAUTION) | 0.2 | 5 |
total | 20 | 500 |
Table 1: Assembling information for the small- and large-scale synthesis reactions of 32P-labeled pppGpp. *10x Relseq buffer contains 250 mM Tris-HCl, pH 8.6; 1M NaCl; 80 mM MgCl2. Abbreviation: pppGpp = guanosine pentaphosphate.
4. DRaCALA screening of the target proteins of (p)ppGpp
5. Quantification and identification of potential target proteins
Figure 2: Overall workflow of the DRaCALA screening process. Protein production from an Escherichia coli ASKA collection is induced, and the cells are lysed. Meanwhile, the recombinant proteins Relseq-His and GppA-His are purified and used to synthesize 32P-labeled pppGpp and ppGpp from 32P-α-GTP. The radioactively labeled (p)ppGpp molecules are then mixed with the lysates, and a 96 pin-tool is used to spot the mixtures onto a nitrocellulose membrane for subsequent exposure to a phosphor storage screen, imaging, and quantification of the radioactive signals. Abbreviations: DRaCALA = Differential Radial Capillary Action of Ligand Assay; (p)ppGpp = guanosine penta- and tetraphosphates; RT = room temperature; IPTG = isopropyl β-d-1-thiogalactopyranoside; GTP = guanosine 5'-triphosphate; SDS-PAGE = sodium dodecylsulfate-polyacrylamide gel electrophoresis ; TLC = thin layer chromatography. Please click here to view a larger version of this figure.
Following the above-described protocol will typically yield two types of results (Figure 3).
Figure 3A shows a plate with relatively low background binding signals (binding fractions < 0.025) from the majority of wells. The positive binding signal from the well H3 gives a binding fraction of ~0.35 that is much higher than that observed for the other wells. Even without quantification, well H3 is remarkable, suggesting that a target protein expressed in well H3 binds to either pppGpp, ppGpp, or both. Indeed, the protein overexpressed in well H3 is the hypoxanthine phosphoribosyltransferase Hpt, which is known to bind (p)ppGpp12,16.
Figure 3: Representative DRaCALA screening plates (to the left) and quantification (to the right). (A) DRaCALA spots of the ASKA Plate-50. The only positive hit, Hpt, gave a strong binding signal standing out in both the spot and the quantitation diagram. (B,C) Two replicate DRaCALA spots of the rearranged plate 31. Black broken circles and arrows indicate the true target proteins of (p)ppGpp, while the red broken circles indicate the false positives. See the text for details. Abbreviations: DRaCALA = Differential Radial Capillary Action of Ligand Assay; (p)ppGpp = guanosine penta- and tetraphosphates; RT = room temperature; IPTG = isopropyl β-d-1-thiogalactopyranoside; GTP = guanosine 5'-triphosphate; SDS-PAGE = sodium dodecylsulfate-polyacrylamide gel electrophoresis ; TLC = thin layer chromatography; Hpt = hypoxanthine phosphoribosyltransferase; PrfC = peptide chain release factor RF3; NadR = NMN adenylyltransferase; HflX = translational GTPase. Please click here to view a larger version of this figure.
The other typical result of the screening is shown in Figure 3B,C. In this plate, several wells showed relatively higher background binding signals than those in Figure 3A. This is clearly visible from the relatively strong inner dots for many wells. Quantification also showed that many wells have binding fractions in the range of 0.02-0.04. A higher background of the binding signal is likely caused by the whole cell lysate being viscous despite the treatments with both DNase I and the endonuclease from S. marcescens, which degrade the released chromosomal DNA. For plates such as this one, it is important to compare the two replicate spots of the plate (step 4.5; Figure 3B,C). Quantification of both plates shows that the authentic positive targets (black circles, wells A10 PrfC, B11 NadR) tend to give consistently high binding fractions.
Notably, some true targets could also give variable binding fractions (Well D5, HflX12) such as the false positives (red circles). The reason for this variability lies in the fact that not all proteins in a library are expressed in soluble form and in required amounts. If the concentration of a protein is close to or just below the Kd value, variable binding results can be expected, even for the true targets. Indeed, large amounts of soluble HflX protein were not obtained from the ASKA strain12. To determine whether these proteins are true binders or not, the potential proteins must be purified to homogeneity and the binding confirmed by using a higher concentration (50-100 µM) of the proteins.
Via this screening, 9 out of 20 known target proteins of (p)ppGpp12 were identified (see the discussion section), validating the usefulness of DRaCALA for this task. Additionally, 12 new targets of (p)ppGpp were discovered and confirmed, demonstrating that DRaCALA is a powerful technique to uncover novel target proteins of (p)ppGpp.
One of the critical steps in performing DRaCALA screening is to obtain good whole cell lysates. First, the tested proteins should be produced in large amounts and in soluble forms. Second, the lysis of cells should be complete, and the viscosity of the lysate must be minimal. The inclusion of lysozyme and the use of three cycles of freeze-thaw are often enough to lyse cells completely. However, the released chromosomal DNA makes the lysate viscous and generates high background binding signal, resulting in false positives as shown in Figure 3B,C. To mitigate this, DNase 1 and/or endonuclease from S. marcescens can be used, and the samples can be incubated for a longer time to degrade the DNA.
Both negative (empty plasmid vector) and positive (known target protein) controls should be used to optimize the conditions for whole cell lysate preparation and the DRaCALA binding assay before performing a large-scale screening. When such an optimal condition is found, it becomes unnecessary to include the controls in the actual screening of each plate. This is because the screening procedure is very short and because the majority of the proteins in a plate are expected to not bind to (p)ppGpp. Therefore, these proteins serve as negative controls when quantifying the binding fractions (Figure 3).
The production of purer 32P-labeled pppGpp and ppGpp is also essential for DRaCALA screening. For instance, the conversion ratio from GTP to pppGpp could vary. Thus, it is important to optimize the pH, the concentrations of magnesium and enzymes used, and the reaction time. Small-scale reactions are therefore important to identify the best condition before setting up a large-scale reaction.
DRaCALA clearly has some advantages and disadvantages (see Roelofs et al.9 for more discussion) when compared to other techniques such as the capture compound technique. First, DRaCALA uses the 32P-labeled (p)ppGpp, which does not affect the chemical structure of (p)ppGpp, thereby preserving its interaction with potential target proteins. Second, once the 32p-(p)ppGpp and cell lysates are prepared, it takes only a week to screen ~60 plates of the E. coli ORFeome library using DRaCALA. Indeed, the short experimental procedure (section 4) allowed the identification of even the proteins that degrade the (p)ppGpp (MutT, NudG)12,17, which the capture compound technique missed18.
However, the use of DRaCALA requires an ORFeome expression library, which is only available for a limited number of model organisms. Besides, the affinity purification tags, which are designed to facilitate protein purification in the ORFeome library, sometimes affect the expression or proper folding of the proteins, producing some false negatives. A new ORFeome library will ideally require the determination as to whether the majority (>80%) of the proteins are expressed in soluble form and in adequate amounts. Such a test also allows the researchers to evaluate the coverage and effectiveness of the DRaCALA screening results.
Despite these limitations, DRaCALA is a powerful technique to successfully uncover novel target proteins of several nucleotide secondary messengers. In principle, DRaCALA could be used for studying any small ligand if it could be labeled by using either radioactive isotopes or even fluorescent dyes.
The authors have nothing to disclose.
The work is supported by an NNF Project Grant (NNF19OC0058331) to YEZ, and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (Nº 801199) to MLS.
32P-α-GTP | Perkinelmer | BLU006X250UC | |
96 x pin tool | V&P Scientific | VP 404 | 96 Bolt Replicator, on 9 mm centers, 4.2 mm Bolt Diameter, 24 mm long |
96-well V-bottom microtiter plate | Sterilin | MIC9004 | Sterilin Microplate V Well 611V96 |
Agar | OXOID – Thermo Fisher | LP0011 | Agar no. 1 |
ASKA collection strain | NBRP, SHIGEN, JAPAN | Ref: DNA Research, Volume 12, Issue 5, 2005, Pages 291–299. https://doi.org/10.1093/dnares/dsi012 | |
Benzonase | SIGMA | E1014-25KU | genetically engineered endonuclease from Serratia marcescens |
Bradford Protein Assay Dye | Bio-Rad | 5000006 | Reagent Concentrate |
DMSO | SIGMA | D8418 | ≥99.9% |
DNase 1 | SIGMA | DN25-1G | |
gel filtration10x300 column | GE Healthcare | 28990944 | contains 20% ethanol as preservative |
Glycerol | PanReac AppliChem | 122329.1214 | Glycerol 87% for analysis |
Hypercassette | Amersham | RPN 11647 | 20 x 40 cm |
Imidazole | SIGMA | 56750 | puriss. p.a., ≥ 99.5% (GC) |
IP Storage Phosphor Screen | FUJIFILM | 28956474 | BAS-MS 2040 20x 40 cm |
Isopropyl β-d-1-thiogalactopyranoside (IPTG) | SIGMA | I6758 | Isopropyl β-D-thiogalactoside |
Lysogeny Broth (LB) | Invitrogen – Thermo Fisher | 12795027 | Miller's LB Broth Base |
Lysozyme | SIGMA | L4949 | from chicken egg white; BioUltra, lyophilized powder, ≥98% |
MgCl2 (Magnesium chloride) | SIGMA | 208337 | |
MilliQ water | ultrapure water | ||
multichannel pipette | Thermo Scientific | 4661110 | F1 – Clip Tip; 1-10 ul, 8 x channels |
NaCl | VWR Chemicals | 27810 | AnalaR NORMAPUR, ACS, Reag. Ph. Eur. |
Ni-NTA Agarose | Qiagen | 30230 | |
Nitrocellulose Blotting Membrane | Amersham Protran | 10600003 | Premium 0.45 um 300 mm x 4 m |
PBS | OXOID – Thermo Fisher | BR0014G | Phosphate buffered saline (Dulbecco A), Tablets |
PEG3350 (Polyethylene glycol 3350) | SIGMA | 202444 | |
phenylmethylsulfonyl fluoride (PMSF) | SIGMA | 93482 | Phenylmethanesulfonyl fluoride solution – 0.1 M in ethanol (T) |
Phosphor-imager | GE Healthcare | 28955809 | Typhoon FLA-7000 Phosphor-imager |
Pipette Tips, filtered | Thermo Scientific | 94410040 | ClipTip 12.5 μl nonsterile |
Poly-Prep Chromatography column | Bio-Rad | 7311550 | polypropylene chromatography column |
Protease inhibitor Mini | Pierce | A32955 | Tablets, EDTA-free |
screw cap tube | Thermo Scientific | 3488 | Microcentifuge Tubes, 2.0 ml with screw cap, nonsterile |
SLS 96-deep Well plates | Greiner | 780285 | MASTERBLOCK, 2 ML, PP, V-Bottom, Natural |
spin column | Millipore | UFC500396 | Amicon Ultra -0.5 ml Centrifugal Filters |
Thermomixer | Eppendorf | 5382000015 | Thermomixer C |
TLC plate (PEI-cellulose F TLC plates) | Merck Millipore | 105579 | DC PEI-cellulose F (20 x 20 cm) |
Tris | SIGMA | BP152 | Tris Base for Molecular Biology |
Tween 20 | SIGMA | P1379 | viscous non-ionic detergent |
β-mercaptoethanol | SIGMA | M3148 | 99% (GC/titration) |